A new study covered by HealthNews indicates that the interaction between two proteins, SUCLA2 and USP10, loses its predictive value in breast cancer once treatment begins. The report was published on August 8, 2026, by the Portuguese health outlet.
According to HealthNews, the finding suggests that the combined presence or activity of these two proteins may serve as a useful indicator before therapy starts, but not during or after it. The report did not specify which type of breast cancer was studied or what form of treatment was involved.
The study's implication is that clinicians should be cautious about relying on this particular protein interaction as a biomarker once a patient has received treatment. Biomarkers are biological signs that help doctors gauge how a disease may progress or how well a patient might respond to a specific therapy. If the predictive value fades with treatment, it could complicate efforts to monitor disease status in real time.
HealthNews did not provide details on the size of the study, the patient population, or the specific methodology used. The report also did not state whether the loss of predictive value was observed across all treatment types or only certain ones.
This is an early-stage finding, and more research will be needed to determine whether the SUCLA2-USP10 interaction could still be useful in other contexts, such as early detection or in patients who have not yet received any form of therapy.
What to watch next: whether follow-up studies can identify alternative biomarkers that maintain their predictive accuracy throughout the course of breast cancer treatment.
